Alison Long
Director/Board Member en TAYSHA GENE THERAPIES, INC. .
Fortuna: - $ al 31/03/2024
Perfil
Alison Long is currently a Director at Taysha Gene Therapies, Inc. She was previously the Chief Medical Officer at Kaleido Biosciences, Inc. and the Chief Medical Officer & Senior Vice President at Freeline Therapeutics Holdings Plc.
Dr. Long holds a doctorate degree from George Mason University and the University of the Witwatersrand.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 01/11/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Cargos activos de Alison Long
| Empresas | Cargo | Inicio |
|---|---|---|
| TAYSHA GENE THERAPIES, INC. | Director/Board Member | 01/11/2023 |
Antiguos cargos conocidos de Alison Long.
| Empresas | Cargo | Fin |
|---|---|---|
| KALEIDO BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 01/06/2022 |
| FREELINE THERAPEUTICS HOLDINGS PLC | Chief Tech/Sci/R&D Officer | 01/11/2021 |
Formación de Alison Long.
| George Mason University | Doctorate Degree |
| University of the Witwatersrand | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| KALEIDO BIOSCIENCES, INC. | Health Technology |
| TAYSHA GENE THERAPIES, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Alison Long
